PIP3 and EGFR Dual Targeting for the Development of a Polypeptide Complex Drug Aimed at the Specific Delivery and Therapy of Anaplastic Thyroid Carcinoma
Molecular Pharmaceutics · 26.09.2026
DOI: 10.1021/acs.molpharmaceut.6c00569 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 26.09.2026. Verfasst von Zehra-Cagla Kahvecioglu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Unit of General, Organic and Biomedical Chemistry, NMR and Molecular Imaging Laboratory, Faculty of Medicine, Pharmacy and Biomedical Sciences, Unive…. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, ErbB Receptors, Peptides, Thyroid Neoplasms. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fond pour la Recherche Médicale en Hainaut, Fonds De La Recherche Scientifique - FNRS, Fédération Wallonie-Bruxelles.
Abstract (Originalsprache)
Anaplastic thyroid carcinoma (ATC) is rare but highly aggressive with a median survival of only four months post-diagnosis. Current treatments offer limited survival benefits, highlighting the urgent need for novel targeted therapies. One of the hallmarks of ATC is the dysregulation of key signaling cascades, particularly the PI3K/AKT/mTOR (PAM) pathway. EGFR overexpression and aberrant PAM signaling are major contributors to ATC aggressiveness. We developed a therapeutic peptide (TP) that disrupts PIP3-dependent protein interactions, thereby inhibiting AKT activation with the final goal of triggering apoptosis. To enhance specificity and reduce systemic toxicity, a vectoring peptide (VP) was designed to bind the EGFR. Both peptides were chemically linked to form a peptide complex (PC). EGFR and AKT expression were assessed in ATC cell lines 8505c and Cal-62. Apoptosis was evaluated via Annexin V flow cytometry and activated caspase 3 immunofluorescent detection. The therapeutic efficacy of PC was assessed in athymic nude mice bearing Cal-62 or 8505c tumors. ATC cells showed elevated AKT activation, with nuclear localization. PC induced significantly greater apoptosis than TP alone. In vivo, PC treatment remarkably reduced the tumor size and enhanced apoptosis. Toxicological analyses showed no morphological damage in major organs attributable to PC. Overall, histology and plasma biomarkers confirmed low systemic toxicity. CYP450 screening suggested a potential interaction with PC, although its nature (e.g., substrate or competitive, allosteric, or mixed inhibitor) remains to be elucidated. This EGFR/PIP3-targeted PC demonstrates potent antitumor activity and limited toxicity in ATC models by inhibiting the PAM pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of General, Organic and Biomedical Chemistry, NMR and Molecular Imaging Laboratory, Faculty of Medicine, Pharmacy and Biomedical Sciences, University of Mons, Avenue Victor Maistriau 15, Mendeleïev building, B-7000…
- Therapeutic Chemistry and Pharmacognosy Unit, Faculty of Medicine, Pharmacy and Biomedical Sciences, University of Mons, Chemin du Champ de Mars 25, B-7000Mons, Belgium.
- Histology Unit, Faculty of Medicine, Pharmacy and Biomedical Sciences, University of Mons, Pentagon building, Avenue du Champ de Mars 6, B-7000Mons, Belgium.
- Department of Pathological Anatomy, Erasme Hospital, Faculty of Medicine, Campus Erasme, CP 556, Route de Lennik, 808, 1070Brussels, Belgium.
- Center for Microscopy and Molecular Imaging (CMMI), Rue Adrienne Bolland 8, B-6041Gosselies, Belgium.
- Human Anatomy and Experimental Oncology Unit, Faculty of Medicine, Pharmacy and Biomedical Sciences, University of Mons, Pentagon building, Avenue du Champ de Mars 6, B-7000Mons, Belgium.
ORCID-Profile: Zehra-Cagla Kahvecioglu, Rachel Baillif, Alison Daubry, Ami Gloria Toulehohoun, Charlotte Rogien, Amandine Nachtergael, Pierre Duez, Denis Nonclercq, Myriam Remmelink, Sophie Laurent, Sven Saussez, Carmen Burtea
Förderung
- Fond pour la Recherche Médicale en Hainaut
- Fonds De La Recherche Scientifique - FNRS
- Fédération Wallonie-Bruxelles
- F?d?ration Wallonie-Bruxelles
- Fond pour la Recherche M?dicale en Hainaut
Zitieren
APA
Kahvecioglu, Z. C., Baillif, R., Daubry, A., Toulehohoun, A. G., Rogien, C., Sotche, M. S., Nachtergael, A., Duez, P., Nonclercq, D., Remmelink, M., Laurent, S., Saussez, S., & Burtea, C. (2026). PIP3 and EGFR Dual Targeting for the Development of a Polypeptide Complex Drug Aimed at the Specific Delivery and Therapy of Anaplastic Thyroid Carcinoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00569
Vancouver
Kahvecioglu ZC, Baillif R, Daubry A, Toulehohoun AG, Rogien C, Sotche MS, et al. PIP3 and EGFR Dual Targeting for the Development of a Polypeptide Complex Drug Aimed at the Specific Delivery and Therapy of Anaplastic Thyroid Carcinoma. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00569
BibTeX
@article{Kahvecioglu2026,
author = {Kahvecioglu, Zehra-Cagla and Baillif, Rachel and Daubry, Alison and Toulehohoun, Ami Gloria and Rogien, Charlotte and Sotche, Merveil Steve and Nachtergael, Amandine and Duez, Pierre and Nonclercq, Denis and Remmelink, Myriam and Laurent, Sophie and Saussez, Sven and Burtea, Carmen},
title = {PIP3 and EGFR Dual Targeting for the Development of a Polypeptide Complex Drug Aimed at the Specific Delivery and Therapy of Anaplastic Thyroid Carcinoma},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.6c00569}
}
EUVIMED